Microarray Immunosignature System Diagnoses Cancer
By LabMedica International staff writers Posted on 04 Aug 2014 |
An innovative technique for early disease detection, called immunosignaturing, relies on a multiplexed system in which the entire population of antibodies circulating in blood at a given time is profiled.
This immunosignature approach leverages the response of antibodies to disease-related changes, as well as the inherent signal amplification associated with antigen-stimulated B-cell proliferation. This would be a substantial improvement over highly specific bioassays that can only test for a single biomarker antibody, often with substantial misidentification or inadequate sensitivity.
Scientists at the Arizona State University (Tempe, AZ, USA) analyzed serum samples from 20 samples each from five cancer patient cohorts, along with 20 non-cancer patients to establish reference immunosignatures. Once reference immunosignatures were established, the technique was tested in blind evaluation of 120 independent samples covering the same diseases.
The technique relies on a microarray consisting of thousands of random sequence peptides, imprinted on a glass slide. The peptides used were 20 unit amino acid chains, randomly composed. When less than a microliter of serum is spread across the microarray, antibodies in the blood selectively bind with individual peptides, forming a portrait of immune activity resulting in an immunosignature. The microarrays are scanned at 10-μm resolution at 647-nm wavelength by a High-Resolution Microarray Scanner (Agilent Technologies; Santa Clara, CA, USA) using high laser power and 70% gain for the photomultiplier tube.
To further assess the diagnostic power of immunosignaturing, over 1,500 historical samples comprising 14 different diseases, including 12 cancers were tested. In this case, 75% of the samples were used in the training phase and the remaining 25% subjected to blind testing. Remarkably, an average diagnostic accuracy of over 98% was achieved, demonstrating the suitability of immunosignaturing for the simultaneous classification of multiple diseases. In another trial, 14 separate diseases were distinguished from one another as well as from healthy controls, through immunosignatures. Among the cancers tested were three different stages of breast cancer, four different brain cancers, two pancreatic diseases, ovarian cancer and two different blood cancers.
The presence of 10,000 peptides on each microarray chip allows for enhanced sensitivity, owing to the large number of different possible signals elicited. The technology is also highly flexible in terms of handling and processing. A dried sample of blood, collected on filter paper and mailed to a study facility can be used to generate an immunosignature, permitting frequent health monitoring at low cost. The study was published on June 23, 2014, in the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Related Links:
Arizona State University
Agilent Technologies
This immunosignature approach leverages the response of antibodies to disease-related changes, as well as the inherent signal amplification associated with antigen-stimulated B-cell proliferation. This would be a substantial improvement over highly specific bioassays that can only test for a single biomarker antibody, often with substantial misidentification or inadequate sensitivity.
Scientists at the Arizona State University (Tempe, AZ, USA) analyzed serum samples from 20 samples each from five cancer patient cohorts, along with 20 non-cancer patients to establish reference immunosignatures. Once reference immunosignatures were established, the technique was tested in blind evaluation of 120 independent samples covering the same diseases.
The technique relies on a microarray consisting of thousands of random sequence peptides, imprinted on a glass slide. The peptides used were 20 unit amino acid chains, randomly composed. When less than a microliter of serum is spread across the microarray, antibodies in the blood selectively bind with individual peptides, forming a portrait of immune activity resulting in an immunosignature. The microarrays are scanned at 10-μm resolution at 647-nm wavelength by a High-Resolution Microarray Scanner (Agilent Technologies; Santa Clara, CA, USA) using high laser power and 70% gain for the photomultiplier tube.
To further assess the diagnostic power of immunosignaturing, over 1,500 historical samples comprising 14 different diseases, including 12 cancers were tested. In this case, 75% of the samples were used in the training phase and the remaining 25% subjected to blind testing. Remarkably, an average diagnostic accuracy of over 98% was achieved, demonstrating the suitability of immunosignaturing for the simultaneous classification of multiple diseases. In another trial, 14 separate diseases were distinguished from one another as well as from healthy controls, through immunosignatures. Among the cancers tested were three different stages of breast cancer, four different brain cancers, two pancreatic diseases, ovarian cancer and two different blood cancers.
The presence of 10,000 peptides on each microarray chip allows for enhanced sensitivity, owing to the large number of different possible signals elicited. The technology is also highly flexible in terms of handling and processing. A dried sample of blood, collected on filter paper and mailed to a study facility can be used to generate an immunosignature, permitting frequent health monitoring at low cost. The study was published on June 23, 2014, in the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Related Links:
Arizona State University
Agilent Technologies
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Immunology News
- AI Predicts Tumor-Killing Cells with High Accuracy
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form